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INTRODUCTION
At first sight, small peptides would appear not to play a significant role in human protein metabolism. The classical view is summarized by models describing the flux of free amino acids between plasma and tissue amino acid and protein pools. However, a large part of amino acid flux is as short-chain peptides. First, ingested protein (7G100 g/d) is presented to the gut mucosa in the form of peptides with a chain length of two to six amino acids . A significant proportion of the amino acids released during tissue protein degradation (20CL300 g/d) is in the form of di-and tripeptides, which are subsequently hydrolysed to free amino acids within the intracellular compartment. This process is extremely rapid, and the existence of a peptide pool has been shown only by use of a specific peptidase inhibitor, bestatin (Botbol & Scornik, 1983) . Finally, the renal brush border, and to a lesser extent liver and muscle, appear to be the sites of extracellular hydrolysis of significant quantities of circulating peptides. These processes are relevant to the form in which nitrogen should be given to patients receiving nutritional support via the intravenous or nasoenteral routes. Thus, synthetic di-and tripeptides have been considered as a vehicle for amino acids which are themselves unstable or sparingly soluble. Considerable effort has also been expended in determining whether there is any need to predigest dietary protein to small peptides, in order to improve N absorption in patients with impaired gastrointestinal function. Finally, the problem of 'bitter peptide' release during partial enzymic hydrolysis of food proteins has also been investigated fully.
In the present review, advances in a number of different areas of peptide research will be discussed in order to answer the question 'Is there a place for peptides in clinical protein nutrition? '
APPLICATION OF PEPTIDES TO ORAL NUTRITION
Most manufacturers of liquid enteral diets produce some diets in which the protein has been partially hydrolysed or replaced with free amino acids. The rationale is that 'predigestion' of the protein may improve N absorption in patients whose intestinal function is impaired through significant loss of absorptive surface (e.g. small bowel resection) or digestive function (e.g. following pancreatectomy). This section will briefly review the major mechanisms of uptake of protein amino acids. In addition, experimental evidence which suggests that peptide uptake in the small intestine may be of great nutritional significance will be described in detail.
PEPTIDES I N H U M A N NUTRITION
and significance of luminal protein hydrolysis by gastric, pancreatic and solubilized brushborder peptidases is reviewed in some detail elsewhere (Gray & Cooper, 1971 ; Freeman et al. 1983; Desnuelle, 1986; Puigserver rt al. 1986; .
Sites of protein assimilation: small and large intestine?
Assimilation of dietary protein occurs mainly in the proximal jejunum (Silk et al. 1979) , although the ileum has considerable digestive and absorptive capacity . Animal studies (Curtis et al. 1978) have implicated the colon as the major site of assimilation of endogenously derived protein (intestinal secretions, secreted plasma proteins and desquamated cells). However, despite this, there is no quantitative information on the absorptive capacity of the normal human small bowel. Two indirect lines of evidence suggest that small, but significant, quantities of protein pass from the lumen of the ileum into the colon.
First, in patients with ileostomy (Chacko & Cummings, 1988 ) N losses from the small bowel (mainly as protein and small peptides) have been shown to be significant (approximately 10-20% of intake). The microflora of the large intestine are capable of digesting endogenous proteins (e.g. mucins) in vitro (Gibson et al. 1988a,b) and dietary proteins in vitro (MacFarlane & Allison, 1986; MacFarlane et al. 1986 ) and in vivo (MacFarlane et al. 1986) . Luminal hydrolysis of protein, to small peptides, occurs by the action of pancreatic enzymes and secreted and cell-wall bound bacterial peptidases. Peptide hydrolysis appears to be the rate-limiting step for subsequent fermentation of amino acids to short-chain fatty acids, dicarboxylic acids, phenolic compounds and ammonia, all of which may be absorbed or metabolized by the large intestine, (MacFarlane & Allison, 1986; Grimble, 1989; . There is, thus, the potential for salvage of the carbon and N moieties of protein malabsorbed by the small bowel which is not incorporated into faecal bacterial mass.
Free amino acid transport
There appear to be four major, group-specific, active transport systems in the mammalian enterocyte (Wellner & Meister, 1981; Matthews & Payne, 1980; Matthews, 1984) : ( I ) monoamino, monocarboxylic (neutral amino acids), (2) glycine, proline, hydroxyproline, (3) dibasic amino acids and cysteine, (4) dicarboxylic (acidic) amino acids.
Further definition of these systems in the intact intestine is complicated by the presence of multiple transport systems within each group, and differing transport characteristics for the same amino acid, at the enterocyte brush border and basolateral membrane (see Matthews & Burston, 19846; Semenza & Corcelli, 1986) .
Peptide transport
The close connection between brush-border membrane hydrolysis of peptides and their uptake (Adibi, 1971 ; Matthews, 1 9 7 5~; Silk et al. 1976; Nicholson & Peters, 1978 Tobey et al. 1985) is consistent with a 'dual hypothesis' of peptide assimilation. In this scheme, a di-or tripeptide can be absorbed intact by a system which is distinct from any amino acid transporter. Peptides which are absorbed intact are hydrolysed intracellularly. Alternatively, constituent amino acids or smaller peptide fragments may be absorbed after brush-border membrane hydrolysis of the peptide. The evidence for intact tetrapeptide uptake is conflicting and most studies have shown a requirement for prior brush-border hydrolysis (Silk, 1981 ; , 1989 .
The strong relationship between hydrophobicity and affinity for transport of the neutral amino acids does not hold when they are presented to the luminal mucosa in the form of homologous dipeptides (Burston et al. 1982; . Indeed, it is hard to discern any strong structure-activity relationship for intact di-and tripeptide transport. Thus, it is still not clear whether there is one peptide carrier of broad specificity whose activity may be allosterically modified by the more hydrophobic peptides (Matthews & Burston, 1984a) , or whether there are multiple carriers (Rubino et al. 1971) . Microelectrode and brush-border membrane vesicle studies have shown that dipeptide uptake is 'driven ' by a hydrogen ion, not a sodium ion gradient (Boyd & Ward, 1982; Ganapathy et al. 1981 Ganapathy et al. , 1984 Ganapathy & Leibach, 1983 Rajendran et al. 1985) .
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Q U A N T I T A T I V E ASPECTS OF D I E T A R Y P R O T E I N ASSIMILATION
Perfusion studies
Studies in young animals have suggested that dipeptide transport is of greater quantitative significance than free amino acid transport during early growth (Guandalini & Rubino, 1982; Miller et al. 1984) . Likewise in human intestinal perfusion studies di-and tripeptide uptake was inhibited less than free amino acid uptake following 2 weeks of starvation (Vasquez et al. 1985) . In a number of human and animal meal-feeding and intestinal-perfusion studies, the rate of absorption of individual amino acid residues was faster and more even from partially hydrolysed protein (containing most amino acids in peptide form) than from its equivalent free amino acid mixture Silk et al. 1980; Grimble et al. 1986; Rerat et al. 1988 ). These findings suggest that there may be an absorptive advantage in using protein hydrolysates rather than free amino acids in enteral diets.
This issue is contentious, and the so-called 'kinetic advantage' may be an artefact of the steady-state perfusion model. It has been argued that amino acid transport saturates at lower concentrations than dipeptide transport, such that uptake during perfusion at 100 mmol a-amino(NH,)-N/l would occur under saturating and non-saturating conditions respectively for amino acids and peptides. This situation may be reversed at lower concentrations (Hegarty et al. 1982) and since during continuous nasoenteral nutrition the rate of infusion of amino acids (approximately 400 ,amol/min) is similar to that during intestinal perfusion at 30-40 mmol a-NH,-N/I (approximately 470 ,umol/min), there may be no absorptive advantage for protein hydrolysates over free amino acids. However, other factors also affect uptake. The starter protein, the method of enzymic hydrolysis and the chain length of constituent peptides have all been shown to alter uptake of amino acid residues from a number of protein hydrolysates Keohane et al. 1985) . Large alterations in the average peptide chain length of lactalbumin hydrolysates markedly affected uptake of amino acid residues . A small increase in the chain length of ovalbumin and casein hydrolysates from di-and tripeptides to tetra-and pentapeptides (Table 1 ) markedly reduced N uptake from these preparations, at both high and low perfused concentrations (Grimble et al. 1987; Rees el al. 1988~) . As in previous animal studies (Adibi & Morse, 1977; Smithson & Gray, 1977; Burston et al. 1979) it appears that in the absence of luminal pancreatic enzymes, brush-border hydrolysis of tetra-and pentapeptides is rate-limiting in the uptake of constituent N. Since the hydrolysate studied by Hegarty et al. (1982) contained predominantly medium-chain peptides it is possible that if a short-chain lactalbumin hydrolysate had also been studied a different conclusion might have been drawn.
The effect of the other hydrolysis variables on uptake have not been studied in such detail. Peptide sequence may influence uptake. Thus, if two hydrolysates of identical chainlength profile were produced from the same protein by two groups of peptidases with different bond specificity, this would markedly affect the sequence and hydrophobicity of Mean values were significantly different (assessed by the randomization test for matched pairs): P < 005, ** P < 0.02. constituent peptides in these two hypothetical mixtures. It would be of interest to determine if this had such marked effects on absorption of N and amino acids as does chain length. This would clearly be an area for fruitful investigation.
Animal feeding studies
A number of studies have examined the relative nutritional value of diets containing whole protein, partially digested protein or free amino acids. Only those which have been controlled for amino acid composition are discussed.
Diets based on casein or the identical amino acid mixture produce equal growth rates in young, healthy rats (Itoh et al. 1973 ). However, a whole-protein diet produced higher N retention, tissue weight and plasma protein levels in burned guinea-pigs than did the equivalent free amino acid diet (Trocki et al. 1986 ). These diets differed in one important respect. The amino acid diet was based on the amino acid composition of the protein, determined after complete acid hydrolysis, and no correction was apparently made for the loss of the carboxamide groups of asparagine and glutamine during acid hydrolysis. Since amide N can account for up to 20% of protein-N, the composition of an 'equivalent' amino acid mixture has to be corrected, either by adding ammonium ions or the dicarboxylic acids with their amides in the ratio found in the native protein by sequence analysis. Both types of correction of the composition of a free amino acid diet were without effect on the growth rate of young rats (Itoh et al. 1973) . Similarly, no difference was found in growth rates, food intake or the composition of peripheral tissues when rats received a hydrolysed whey protein diet or one of 'equivalent ' (but uncorrected) amino acid composition . What is surprising is that this small difference had such a marked effect on tissue N retention in burned animals. Provision of glutamine, not glutamate, in oral diets may be of importance during episodes of sepsis or trauma. Evidence reviewed by Windemueller (1982) suggests that the enterocyte can metabolize glutamine from luminal as well as arterial sources. The presence of glutamine in the small intestinal lumen of the rat has been shown to increase total enterocyte glutamine utilization, even though that from arterial sources was reduced. One would, thus, expect that glutamine supply to the small intestines of the two groups of burned animals was significantly different (Trocki et al. 1986 ) because of the subtle difference between the two diets. Oral supplementation with glutamine has been shown to reduced mortality in guinea-pigs treated with doses of methotrexate which induced necrotizing enterocolitis (Fox et al. 1988) . In a rat feeding study ) the group of animals fed on a proteinhydrolysate-based diet which contained glutamine showed marked caecal and colonic hypertrophy and hyperplasia, similar in magnitude to that seen during dietary fibre supplementation Rolandelli et al. 1986 ). It is not clear whether the tropic effect was due to the glutamine content or to malabsorption of the hydrolysate and its fermentation in the large bowel.
Feeding studies in man
Normal gut function. In two studies where the amino acid content of all diets was carefully controlled there appeared to be no difference in overall absorption or metabolic utilization of protein, protein hydrolysates, or the equivalent amino acid mixtures, in subjects with normal small bowel function (Silk et al. 1979; Moriarty et al. 1985) . Thus, in normal man there is sufficient absorptive capacity in the small intestine for efficient assimilation of whole protein.
Impaired gut function. For patients with moderately impaired gastrointestinal function there appears to be no nutritional superiority of protein hydrolysates over whole protein (Rees et al. 19886) . In pancreatectomized patients (Steinhardt et al. 1989 ) absorption of a lactalbumin hydrolysate was significantly greater (91 YO) than that of lactalbumin (61 YO).
What is most remarkable about this study is that over half the protein was assimilated in the absence of pancreatic enzymes, suggesting that the activity of brush-border endopeptidases against peptic digests of whole protein is quantitatively significant (Song et al. 1986 ). In patients with 60-150cm of the jejunum remaining, two diets containing protein or partially hydrolysed protein were equally well absorbed (McIntyre et al. 1986 ). When absorptive area was more severely reduced (50-80 cm jejunum) no difference was observed in N balance, N absorption or ['3C ]leucine kinetics when patients received a wheyprotein-hydrolysate-based or equivalent amino acid-based enteral diet (Rees et al. 1988 a). The whey protein hydrolysates used in both studies contained mainly tetra-and pentapeptides and it is possible that their uptake was limited by brush-border hydrolysis.
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C O N C L U S I O N S A N D P E R S P E C T I V E S
It now seems that a significant proportion of dietary N is absorbed in the form of di-and tripeptides. The peptide and free amino acid transport systems of the small intestine may differ in their handling of the wide variety of dietary proteins, especially in relation to the non-essential amino acids. Thus, where a free amino acid is poorly transported by an easily saturable system its uptake may be faster via the peptide transport system if it is presented in peptide form. A second function of the peptide transport system may be to relieve competition for transport between free amino acids which share the same carrier. This may be especially true in cases where poor protein quality and malabsorption coexist with a high requirement for amino acid residues (e.g. rapid growth in infants).
Despite the differences in absorption of partial hydrolysates of protein or their equivalent amino acid mixtures observed in human intestinal perfusion experiments, there have been relatively few controlled studies of the nutritional efficacy of proteins, hydrolysates or free amino acids in man. At present, only one study has shown that predigestion of protein increases N absorption in pancreatectomized patients. Where absorptive area is severely reduced (e.g. inadequate short bowel syndrome) there appears to be no advantage of medium-chain protein hydrolysates over whole protein or free amino acids. However, recent perfusion studies suggest that brush-border hydrolysis of the peptides of mediumchain hydrolysates may be rate limiting to uptake. It is, thus, possible that hydrolysates containing mainly di-and tripeptides may provide an absorptive benefit to patients with severely reduced intestinal absorptive area.
APPLICATION OF PEPTIDES TO INTRAVENOUS NUTRITION
P E P T I D E S Several lines of research suggest that the capacity of the human body to hydrolyse circulating peptides is quite large. Significant quantities of peptides may cross the intestinal barrier intact. The kidney appears to be a major site of digestion of circulating peptides and recapture of their constituent amino acids. A number of recent infusion studies with synthetic dipeptides have shown that they are rapidly hydrolysed and metabolized. Finally, peptides were widely used in intravenous nutrition for many years, in the form of partially hydrolysed protein. Although the use of hydrolysates has now been discontinued in favour of solutions of free amino acids, early studies suggested that their constituent peptides were fairly well utilized.
T R A N S L O C A T I O N O F P E P T I D E S A C R O S S T H E G A S T R O I N T E S T I N A L B A R R I E R
Two comprehensive reviews have challenged the view that only free amino acids enter the portal circulation after a protein meal (Matthews, 1975 b; Gardner, 1984) . It was noted that significant quantities of hydroxyproline-containing peptides were excreted in urine following a meal of partially hydrolysed gelatin (Prockop et al. 1962; Hueckel & Rogers, 1970) . Since this represented an increase in excretion over basal levels, some of these peptides must have escaped degradation by the enterocyte and entered the portal circulation. Proline-containing peptides are often thought to be a special case because of the resistance of the prolyl bond to hydrolysis (Faull et al. 1976; Walter et al. 1980; Charpentier et al. 1984 ), but peptidaemia in portal blood has also been noted after casein feeding in dogs (Christensen, 1949) , or after perfusion of the small intestine of guinea-pigs with solutions of partially hydrolysed Lasein (Gardner et al. 1983 ). In the latter study, a surprisingly wide variety of amino acids were found in peptide-bound form in the blood.
According to the authors, this accounted for as much as 15 YO of net amino acid release into the portal circulation. These findings suggest that pathways exist for efficient hydrolysis of translocated peptides because, if 15% of dietary N enters the circulation in peptide form (Gardner et al. 1983) , only a small percentage leaves as such, about 4 % of total N excretion in man (Lidstrom & Wretlind, 1952; .
T H E R O L E O F T H E K I D N E Y I N D I S P O S A L O F C I R C U L A T I N G P E P T I D E S
The mechanism by which the kidney salvages circulating peptide-bound amino acids is, in some respects, similar to assimilation of peptides by the small intestine. The same membrane-bound peptidases with distinctive structure are found in both organs (Kenny & Maroux, 1982) and brush-border membrane vesicle preparations from both tissues are capable of concentrative uptake of intact dipeptides, driven by a proton gradient (Ganapathy & Leibach, 1983 Ganapathy et al. 1984 . Uptake kinetics of amino acids, peptides and maltose in the perfused renal tubule or whole kidney also appear to be remarkably similar to that in the perfused small intestine (Silbernagl, 1977; Silbernagl & Vokl, 1977; Lowry et al. 1985) . Peptides may also be assimilated by luminal endocytosis and intralysosomal degradation to amino acids and peptides (Galaske et al. 1979; Maack et al. 1979; Carone & Peterson, 1980; Rabkin & Kitaji, 1983) . It is not entirely clear how the structure of a peptide determines whether it is reabsorbed by this mechanism or by brush-border hydrolysis and uptake of small peptides and free amino acids. Certain peptide hormones which are modified by cyclization, extensive disulphide bridging, or N-and Cterminal blocking (e.g. oxytocin and luteinizing hormone releasing hormone), making them resistant to exopeptidase hydrolysis, do not appear to be hydrolysed at the brush border but may be absorbed by pinocytosis (Peterson et & Kitaji, 1983) .
One particular peptide family, the casomorphins, provide an insight into disposal of circulating peptides. Casomorphins (residues (60-70) are contained within the 'bitterpeptide' (residues 53-79) described by Clegg er al. (1974), which may be released from casein during production of partial enzymic hydrolysates of casein for clinical use. All sequences from 60-62 up to 6&70 have been shown to possess opioid activity (see Schlimme et al. 1989) . The presence of four proline residues within the sequence (Tyr-ProPhe-Pro-Gly-Pro-Ile-Pro-Asn-Ser-Leu) confers resistance to digestion by pancreatic enzymes (Gardner, 1985; Petrilli et al. 1987 ) and casomorphins may be translocated across the intestinal wall after milk ingestion (Gardner, 1984) . A careful study of the uptake of Tyr-Pr~-[~H]Phe-Pro-Gly by renal tubule brush-border membrane vesicles has suggested the mode of disposal of circulating casomorphins (Miyamoto et al. 1987 ). There was no intact uptake of this pentapeptide, but hydrolysis by brush-border dipeptidyl peptidase IV (EC 3.4.14.5) (at the -Pro-Phe-and -Pro-Gly-bonds) released glycine and di-and tripeptide fragments which were absorbed.
I N F U S I O N S T U D I E S W I T H S Y N T H E T I C D I P E P T I D E S
The fate of injected glycine homopeptides, which are relatively poorly hydrolysed, is markedly affected by their chain length (Adibi & Krzysik, 1977; Krzysik & Adibi, 1979; Adibi & Morse, 1982) . Although the liver was a significant site of diglycine utilization, kidney uptake and hydrolysis became the predominant pathways of disposal of tri-and tetraglycine. This probably reflects the fact that peptidases of the kidney tubule have high affinity for and activity towards tri-and tetrapeptides which remain in the circulation for extended periods. Recent comparative studies of two dipeptides which are more or less resistant to hydrolysis (glycylglycine and glycylleucine respectively) have highlighted the role of skeletal muscle and the liver in their disposal (Lochs et al. 1986, 1988) . There was no evidence of intact uptake by the liver, and the results were consistent with surface hydrolysis by liver cell membrane peptidases. Leucine and glycine uptake by skeletal muscle was higher during infusion of glycylleucine than during infusion with glycine and leucine. The more resistant peptide, glycylglycine, was predominantly metabolized by the kidney, and more slowly cleared from the circulation. Hind-limb balance studies in post-operative anaesthetized dogs have also shown that the amino acids of infused alanylglutamine are extracted by skeletal muscle almost as well as from mixtures of alanine and glutamine (Roth et al. 1988) . Attempts have been made to replace amino acids with di-and tripeptides in long-term animal total parenteral nutrition (TPN) models. In particular, a mixture of Nterminal glycine dipeptides was shown to be as effective as the equivalent amino acid (Steinhardt et al. 1984) . Similar results have been obtained in rats infused with alanyltyrosine (Daabees & Stegink, 1979) , glycyltyrosine (Neuhauser 1983 , and alanylglutamine (Albers et al. 1984 ).
L A R G E -S C A L E U S E O F I N T R A V E N O U S P R O T E I N H Y D R O L Y S A T E S Successful intravenous (IV) nutrition was first introduced, over 50 years ago, by Robert
Elman who infused mixtures of electrolytes, glucose and amino acids (as partially hydrolysed protein) into patients in sufficient quantities to reverse the oedema and weightloss of long-term malnutrition (Elman, 1947) . Commercial production and large-scale clinical use of IV protein hydrolysates continued until the early 1980s in Europe and the USA, but they have now been replaced by solutions of L-amino acids.
Historical reviews have suggested that the change was due to the inferiority of peptidecontaining hydrolysates to solutions of free amino acids in a number of respects (Table 2 ; Levenson & Fisher, 1974; Levenson et al. 1984; Winters et al. 1984) . There were several interesting features about large-scale use of IV protein hydrolysates. First, they were a source of IV L-amino acids, at a time when synthetic methods for producing non-racemic mixtures of amino acids were unavailable. They contained considerable quantities of peptides, but this was not considered to be of benefit-rather the reverse. With regard to current interest in IV synthetic dipeptides, the large body of literature on IV protein hydrolysates is extremely relevant. Comparative studies of IV hydrolysates and free amino acid solutions provide an estimate of the capacity of the body to clear infused peptides from the circulation. Finally, the switch to free amino acids was probably driven by marketing and research pressures as much as by reservations about the efficacy of protein hydrolysates. It should be noted that none of the perceived problems with hydrolysates proved to be insurmountable (Table 2) .
Comparison with free amino acids
Of three prospective, controlled clinical trials which have compared IV hydrolysates with IV amino acids or oral protein only one has shown hydrolysates to be as effective in 
Adapted from Chataud er a/. (1988).
maintaining patients in N equilibrium (Tweedle et al. 1973) . This was partly due to the poor amino acid pattern of two preparations which contained limiting amounts of cysteine, valine or phenylalanine (Patel et al. 1973 ; Long et al. 1974). As will be discussed later, an additional problem of the processes used in manufacturing these hydrolysates is the selective loss of some amino acids ( Table 3) .
Pept iduria
In a number of early studies it was observed that at very high infusion rates a significant proportion of the peptide fraction of the hydrolysate was excreted in the urine (Silber & Porter, 1949; Christensen, 1950; Christensen et al. 1955 ). Post-operative stress in parenterally-fed patients also increased excretion of the peptide moiety from 30 to 70 YO (Lidstrom & Wretlind, 1952; Vinnars et al. 1969 Vinnars et al. , 1974 , and it was concluded that part of the peptide moiety was intrinsically resistant to renal hydrolysis and reabsorption. The identity of the resistant peptide species remains unclear, but could possible have been prolyl peptides (Hueckel & Rogers, 1970; Walter et al. 1980) or peptides modified by condensation with sugars during heat sterilization (Christensen et al. 1955) . Certainly, the kidney has a large capacity for recapture of small peptides and the peptidases of the renal tubule brush border are both abundant and of wide specificity (Sterchi & Woodley, 1980; Walter et al. 1980 ; Kenny & Maroux, 1982; Tobey et al. 1985) . This has been shown in one study where urinary excretion of glycyl dipeptides was insignificant when they provided the only IV N source for baboons (Steinhardt et al. 1984) .
It is more likely that a large part of the 'peptiduria' observed in earlier studies was artifactual for the following reason. Pyrrolidone carboxylic acid (PCA) is formed from glutamine by intramolecular rearrangement and will only react with ninhydrin after acid treatment has opened the ring structure. Since the classical method for assessing peptiduria has been to measure a-NH,-N before and after acid hydrolysis, the presence of significant quantities of excreted PCA will lead to an overestimation of ' peptiduria '. Approximately two-thirds of the glutamate and glutaqine residues of casein were converted to PCA during production of one IV hydrolysate (Aqvist & Wretlind, 1957) , and since it is excreted unchanged, during IV infusion it would have made a major contribution to ' peptiduria'. Interestingly, this preparation had acceptably low toxicity (lethal dose about 450 g given as a single injection; Goldberg & Wretlind, 1947) and this would cast some doubt on the alleged toxicity of PCA (e.g. Heller et al. 1967; Stehle et al. 1984) . What is clear is that conversion of glutamine to PCA, in IV preparations, will prevent utilization of this amino acid. Clinical and experimental use of IV protein hydrolysates, therefore, suggests that the peptide moiety was substantially utilized, about 30 YO for one preparation (Lidstrom & Wretlind, 1952) . Unfortunately, the chain length of these peptides is not known, other than that they were 'dialysable'.
T H E R A T I O N A L E F O R I N T R A V E N O U S P E P T I D E S Synthetic peptides
Synthetic peptides are being investigated for IV use for two reasons. Some amino acids (e.g. tyrosine, cystine) are sparingly soluble in free form but in heteropeptide form are very soluble. This is mainly a problem of IV solution formulation and will be discussed later (Table 4) . A second reason is that there is some evidence that glutamine may be of importance to the septic or traumatized patients and may be provided in the form of alan ylglutamine.
Evidence for a role for glutamine in septic or traumatized patients. During the catabolic response to injury or sepsis the relative rates of protein synthesis and breakdown are altered such that there is net protein breakdown (Rennie, 1985) , in part mediated by a loss of functioning ribosomes-the machinery of protein synthesis (Wernerman et al. 1987) . The proportion of net amino acid efflux from skeletal muscle which comprises glutamine markedly increases during fasting (Magnusson et al. 1 9 8 7~; Wood et al. 1988), or in malnourished and traumatized patients (Askanazi et al. 1980; Furst et al. 1987) . As a consequence, muscle intracellular glutamine concentrations have been shown to be reduced. Rennie and co-workers have suggested that this is related to the characteristics of a glutamine transport system unique to skeletal muscle (Rennie et al. 1986 ). According to this model, net glutamine efflux from skeletal muscle accompanies post-traumatic changes in this Na+-linked glutamine transport system. Taken alone, this would be a metabolic curiosity were it not for the strong correlation between rates of muscle protein synthesis and intracellular glutamine levels (Jepson et al. 1988) . Post-traumatic efflux of glutamine may provide a specific fuel for the gastrointestinal tract (Windemueller, 1982; Souba er al. 1985) and cells of the immune system (Newsholme et al. 1985 (Newsholme et al. , 1987 in order to maintain the barrier function of the former and the ability of the latter to mount an appropriate response. It has, therefore, been proposed that IV amino acid solutions for septic or traumatized patients should be supplemented with glutamine (Furst et al. 1987 ; Wilmore et al. 1988) .
Possible sources of glutamine for intravenous use. The free amino acid is cheap but relatively unstable in solution, being converted to PCA during heat sterilization. In contrast, N-acetylglutamine is stable (but also cheap) and after injection is deacetylated at the renal tubule brush border, liberating glutamine which may be reabsorbed.
Unfortunately, deacetylase activity is limited such that in normal and post-operative subjects the upper limit of utilization is only 5-6 g glutamine/d (Magnusson et al. 1987b) , excess being excreted as N-acetylglutamine. Glutamine may be presented in peptide-bound form. Alanylglutamine has been produced by chemical or enzymic synthesis, and is both stable and soluble (see p. 14). Alternatively, glutamine precursors have been considered for IV use. The ornithine salt of a-ketoglutarate, a-ketoglutarate and glutamine appear to be equally effective in reducing post-operative N losses, muscle polysome disaggregation and the loss of muscle intracellular glutamine (Leander et al. 1985; Wernerman et al. 1987; Hammarkvist et al. 1988 Hammarkvist et al. , 1989 .
Metabolic eficacy of alanylglutamine. In the post-operative dog, hind-limb efflux of glutamine may be reversed by infusion of glutamine itself. In one study alanylglutamine was almost as effective as the free amino acids in bringing muscle into balance or positive balance (Roth et al. 1988) . In order to test whether this is of clinical as well as physiological significance. Fiirst and colleagues have performed a prospective, randomized trial in which TPN mixtures were supplemented with either alanylglutamine + glycyltyrosine or isonitrogenous amounts of alanine + glycine (Stehle et al. 1989) . Peptide supplementation significantly reduced post-operative N losses, and a post-operative reduction in muscle glutamine (about 40 YO in the control group) was not observed. This information, therefore, provides the first confirmation that IV glutamine peptides may confer metabolic benefit to septic or traumatized patients.
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Short-chain protein hydrolysates
Intravenous protein hydrolysates in the form in which they were manufactured are, essentially, a dead issue. However, there have been a number of advances in the enzymology of large-scale protein hydrolysis (Chataud et al. 1986a, b, 1988) . As described before, the absorptive characteristics of a number of short-chain hydrolysates of ovalbumin and casein have been defined (Grimble er al. 1987; Rees et al. 1988~) . The kidney and small intestine appear to handle small peptides in a similar fashion (see p. 7) and, therefore, it seemed possible that a short-chain hydrolysate containing mainly di-and tripeptides (rather than tetra-and higher peptides) would be well utilized as an IV N source. In a crossover study, healthy human subjects were infused with a complete TPN mixture (glucose, lipid, N) at a rate which met daily energy and N requirements. One TPN mixture contained a partial hydrolysate of ovalbumin (about 75% di-and tripeptides, hydrolysate 1, Table I ) and during the second experiment this was replaced with the equivalent amino acid mixture. Excess peptide excretion during the hydrolysate infusion accounted for only 6 % of total N excretion, and this suggests that a large proportion of the hydrolysate was metabolized ).
This preparation differs markedly from the previous generation of IV hydrolysates in that only a small proportion of the constituent amino acids exists in the free form, whilst the majority are in the form of di-to pentapeptides. There may be a number of advantages with these short-chain hydrolysates. Their reduced osmolarity (compared to the equivalent free amino acid mixture) may make them a suitable N source for peripheral administration.
Less than 10 YO of those amino acids which are themselves relatively insoluble or unstable (tyrosine. cystine, glutamine, tryptophan) were found to exist in free form in a short-chain casein hydrolysate (hydrolysate 3, Table 1 ) which comprised 95.5 % di-to tetrapeptides, prepared by a similar method to the ovalbumin hydrolysate (Chataud et al. 1986b) . It is possible that these amino acid residues may prove to be soluble and stable, long-term, in peptide form in this type of preparation. Short-chain hydrolysates for IV use may also be more economical than free amino acids or synthetic peptides, as suggested by Tweedle (1975) .
There are, however, two potential problems with protein hydrolysates. It was noted that dogs or human subjects infused with protein hydrolysates or free amino acid mixtures at very high rates developed nausea and other adverse effects (Madden el al. 1944; Vinnars et al. 1970) . This was related to the glutamate content of these preparations, and the problem was not observed in the clinical setting if an appropriately slow hydrolysate infusion rate was used to provide N requirements over 24 h (Filer & Stegink, 1973) .
A potentially more serious complication with IV protein hydrolysates has been that enzymic hydrolysis of protein may unmask epitopes against which a patient may have developed intolerance, through exposure to the protein in the normal diet (see Ferguson & Watret, 1988) . Although antigenicity testing of IV hydrolysates is well described (US Pharmacopeia, 1980) , the potential seriousness of anaphylactic reactions cannot be overemphasized and has, one suspects, been a major reason for the change to non-allergic amino acids for IV infusion. However, we have been unable to find any reports of anaphylactic reactions to IV protein hydrolysates in the literature, and only one study cites evidence of an allergic type of response, in one subject (Heller et al. 1967) .
The cut-off point for antigenicity appears to be eight to ten amino acid residues, and for one casein hydrolysate the number of casein determinants was markedly reduced by extensive enzymic hydrolysis to small peptides (Knights, 1984) . We have observed that of three short-chain hydrolysates of ovalbumin, lactalbumin and casein prepared by the same method, only one (casein) required further hydrolysis to remove epitopes recognized in the US Pharmacopeia (1 980) test , The reason for this difference is not clear but may be related to particular post-transcriptional modifications to casein (e.g. phosphorylation, glycosylation). Certainly, analysis by gas-liquid chromatography-mass spectrometry (GLC-MS) suggested that the initial hydrolysate contained small quantities of glycopeptides, which could be removed by resin treatment (Ford et al. 1986 ).
C O N C L U S I O N S A N D P E R S P E C T I V E S
The evidence summarized suggests that the human body has a large capacity to metabolize small peptides in the circulation. Two recent studies have, therefore, shown that it is possible to supply daily N requirements, intravenously, as small peptides (Steinhardt et al. 1984; Grimble et al. 1988) .
Synthetic dipeptides provide a way to avoid the problems of stability and solubility which exist with solutions of free amino acids. At the same time, a recent clinical trial of alanylglutamine suggests that it is a safe and effective vehicle for IV administration of glutamine to post-operative patients. Short-chain protein hydrolysates may also have a number of advantages in terms of peripheral administration, amino acid stability and cost.
IV amino acid solutions have replaced peptide-containing preparations, on fairly species grounds. Although these solutions have proved to be an effective means of providing IV N, it is ironic that the renaissance in IV peptide research has come about because of the deficiencies of some of the free amino acids themselves.
PRODUCTION O F SYNTHETIC DIPEPTIDES OR PROTEIN HYDROLYSATES FOR CLINICAL U S E S Y N T H E T I C D I P E P T I D E S
Two methods have been used to synthesize stable and soluble di-and tripeptides, which contain unstable or insoluble amino acids. Conventional methods of synthesis have been applied to production of peptides containing tyrosine, glutamine and cysteine (Stehle et al. Stehle, 1988) . Proteolytic enzymes have also been used to synthesize a number of dipeptides. The largest contribution to the free energy change during hydrolysis of a peptide bond comes from the ionization of the liberated amino and carboxyl groups. Thus, if these groups on two substrate amino acids are 'blocked', then the reverse reaction, peptide-bond synthesis, may be catalysed by the enzyme under mild conditions (Fruton, 1982; Konopinska & Muzalewski, 1983; Jakubke et al. 1985) . The major advantages of the enzyme method are stereospecificity of the reaction, lack of racemization and better economy in large-scale production (Fruton, 1982) .
P R O T E I N H Y D R O L Y S A T E S
At first sight, production of protein hydrolysates for nutritional use would seem to be fairly straightforward but there are a number of conflicting requirements which have to be met during manufacture (Table 5) .
Amino acid adequacy
Trypsin and chymotrypsin have been widely used in production of milk protein hydrolysates (Kilara, 1985 ;  Adler-Nissen, 1986 a) but their bond specificity (Desnuelle 1986 ) and the presence of sequences of the type -Arg-Tyr-, -Lys-Tyr-, -Phe-Tyr-, or -PhePhe-in casein (Lyster, 1972) will result in release of free tyrosine and phenylalanine. Tyrosine is sparingly soluble and, like phenylalanine, may be adsorbed onto activated charcoal during any decolorization steps used in manufacture. It is, therefore, not surprising that there were selective losses of these two amino acids in IV casein hydrolysates produced by pancreatic enzyme digestion ( Table 3 ). The use of other proteolytic enzymes is discussed by Adler-Nissen (1986~).
Taste properties
A second feature of endopeptidase digestion is the release of peptides with strong taste properties (e.g. 'cheesy', 'bitter' or 'interesting'). Although casein is a nutritionally adequate protein, 'bitter' flavours in a hydrolysate will prevent its administration to patients by anything other than the nasoenteral route. The phenomenon of peptide bitterness has been shown to occur if the average hydrophobicity of peptide exceeds 5.86 MJ (1400 cal)/mol (Ney 1978 (Ney , 1979 . This scheme has been further refined (Adler-Nissen, 1986h) . Maximum bitterness also occurs if the hydrophobic amino acid residue is adjacent to, but not at the N or C terminal of small peptides (Matoba & Hata, 1972) . The value of this approach has been demonstrated for partial enzymic hydrolysates of casein, which contain the 'bitter' sequence of residues 53-79 (Clegg et al. 1974) , encompassing the /3-casomorphin sequences (Schlimme et al. 1989) . Exopeptidase digestion of this peptide reduced the Q value (average hydrophobicity) from 1400 cal/mol to -= 1100 cal/mol, by releasing a number of hydrophobic amino acids; bitterness was also reduced 100-fold (Umetsu ef al. 1983; Fullbrook et al. 1987) and the mechanism of the latter change was that hydrophobic residues were either removed from the sequence or were exposed at the C-or N-terminal (Adler-Nissen, 19866) .
Non-bitter hydrolysates may prove to be a useful method of protein-supplementing foodstuffs, in situations where whole protein would be unstable because of the acidity of the food.
Pepride chain length
As described previously, the absorptive properties of a protein hydrolysate may vary with peptide chain length. One group have investigated methods for producing hydrolysates with minimal free amino acid content, but which contain mainly di-, tri-and tetrapeptides (about 95 total amino acids) for use as an enteral and parenteral N source (Chataud et al. 1986a (Chataud et al. ,b, 1988 Grimble et al. 1987 Grimble et al. , 1988 . Several peptidases were added in a carefully controlled sequence, such that each operated at its pH optimum and expressed most activity at primary cleavage sites with little release of free amino acids. The peptide chainlength profiles of hydrolysates, prepared by this method and by the conventional technique of adding all enzymes together, are compared in Table 1 . It can be seen that the product of the sequential enzyme method has a narrower chain-length profile, and low free amino acid content. Since the majority of the 'problem' amino acids are in peptide form, losses during processing have been shown to be minimal (Chataud ef al. 1986a, h, 1988 and  Table  3 ).
Glutamine content
The effect of sequence on the stability of glutamine residues in a number of synthetic peptides for IV use has been carefully investigated (Stehle, 1988) . Unfortunately, this has not been the case with the proteins and hydrolysates currently used in enteral diets. In an interesting review, Robinson & Rudd (1974) determined the effect of sequence of sixty-four pentapeptides of the type Gly-X-Asn-Y-Gly or Gly-X-Gln-X-Gly on the rate of deamidation of the asparagine or glutamine residues. Curiously, asparaginyl residues were less stable than glutaminyl residues, the reverse of the situation for the free amino acids. The presence of an adjacent hydrophobic amino acid in the sequence stabilized the amide group. Other factors affecting stability are discussed in more detail elsewhere (Robinson & Rudd, 1974) .
Liquid enteral diets have several clinical and convenience advantages over powdered diets which must be reconstituted before use. This is a novel situation because there may be extensive deamidation of glutamine and asparagine residues in the protein or peptide moiety of presterilized liquid enteral diets during their long shelf-life. As has been described previously, a high glutamine intake may be of particular value to septic or traumatized patients. Could there be a need to investigate the stability of glutamine residues in liquid enteral diets, as has been done for synthetic peptide-based TPN formulas?
Analysis
Because only a small number of synthetic peptides have been used for 1V nutrition, this has simplified analysis and a number of investigators have reported accurate clearance rates during infusion studies (Stehle et al. 1984; Steinhardt et al. 1984; Lochs er al. 1988; Stehle 1988) .
Complete analysis of protein hydrolysates in terms of amino acid composition, peptide chain-length distribution and constituent peptide sequences is a more complex problem. Although the average peptide chain length of a hydrolysate may be measured from the ratio of detectable a-NH, groups before and after acid hydrolysis, correction is required for the free amino acid content and presence of pyrGlu (see p. 96). Size exclusion chromatography (SEC) of hydrolysates has been claimed to produce a satisfactory distribution profile of short-chain hydrolysates (Knights, 1984) . This technique is valid if the polymers under study have a close chemical equivalence and minimal interaction with the packing, as in the case of maltodextrins (Grimble & Adam, 1989) . In our experience, we have found it almost impossible to suppress ionic, charge-transfer and hydrophobic interactions which occur between peptides and the SEC packing, and it is highly unlikely that this method can be applied to the heterogenous mixture of peptides found in most hydrolysates. Cu(n)-chelation chromatography may be a more valid technique since elution position is strongly dependent on the number of peptide bonds (Rothenbuhler et al. 1979) . Capillary GLC-MS has been used to sequence proteins by analysing the dipeptides released during dipeptidyl peptidase IV digestion (Dizdaroglu & Simic, 1980; Krutzsch, 1983) . Since a nutritional protein hydrolysate may be considered in the same way, we (Ford et al. 1986) and others (Corbett et al. 1987) have used the same technique to analyse short-chain protein hydrolysates and synthetic dipeptides.
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C O N C L U S I O N S A N D P E R S P E C T I V E S Large-scale chemical synthesis of specific di-and tripeptides is a very satisfactory solution to a number of formulation problems in parenteral nutrition. Purification may be relatively straightforward, and purity and stability are easily assessed because of the simplicity of the compounds involved. Whether they can be produced economically without making a significant impact on the price of parenteral amino acid preparations is not yet clear.
There have also been several advances in the biotechnology of large-scale protein hydrolysis. It would be overstating the case to say that hydrolysates can be completely 'engineered ', but two formidable problems (chain length and bad taste) appear to have been overcome. Thus, it is quite feasible to produce protein hydrolysates with superior absorptive properties to their equivalent free amino acid mixtures, but at lower cost.
This line of reasoning can lead to a number of alarming conclusions. First, since peptide uptake in the small intestine is a significant mechanism for N assimilation, is it logical to use free amino acids as the only N source for patients with severely impaired gut function? Second, is there a need for free amino acids in parenteral nutrition at all? Evidence reviewed here suggests that amino acid requirements may be met by infusion of mixtures of synthetic dipeptides or short-chain peptides. It is, thus, possible that peptides will come to play a significant role in clinical nutrition after all.
